Aiming to Buy Tm Bio, Luminex Sets Sights On Greater Slice of Molecular Dx Market | GenomeWeb
Seeking to compete directly in the molecular diagnostics market, Luminex last week announced that it has agreed to acquire Tm Bioscience in a stock-for-stock deal worth roughly $44 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.